On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
Otsuka’s Guadecitabine Misses Primary Targets in Treatment-Naïve AML Patients in PIII
Guadecitabine, Otsuka Pharmaceutical’s next-generation DNA hypomethylating agent, has failed to meet its primary goals in a multinational PIII clinical study in treatment-naïve acute myeloid leukemia (AML) patients, the company and its US subsidiary Astex Pharmaceuticals said on July 31. The…
To read the full story
Related Article
- Otsuka Misses Primary Goal in PIII Guadecitabine Trials
October 16, 2020
BUSINESS
- MSD Set to Match Beyfortus Price for RSV Antibody Enflonsia if Added to NIP
November 12, 2026
- Takeda Files Zasocitinib for Three Psoriasis Indications in Japan
November 12, 2026
- Vital KSK Finds No Evidence of Customer Data Leak after Cyberattack
November 12, 2026
- Toho Bankrolls UK Biotech Developing Alzheimer’s Therapy
November 12, 2026
- Maruishi to Invest 300 Million Yen in Kringle Pharma
November 12, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…